Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13904MR)

This product GTTS-WQ13904MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13904MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12797MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ11069MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ7644MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ86MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ5891MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ15737MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ11492MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ517MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW